A Phase I Study to Study the PK and Safety of Single Doses of STS101, DHE Injection and Nasal Spray in Healthy Subjects

Status:
Completed

Trial end date:
2018-11-07

Target enrollment:

Participant gender:

Single-center, single-dose, open-label, 2-part, 3-period crossover (in each part), pharmacokinetic and safety study.

Phase 1

Satsuma Pharmaceuticals, Inc.

Dihydroergotamine